3 days Ago
Patients with low-risk cancers undergoing active surveillance face a favorable long-term prognosis. David Haggstrom, M.D.
, MAS, makes the case that it's time for the medical field to help manage the anxiety caused by waiting. Dr. Haggstrom, a physician-researcher with Regenstrief Institute, the Veterans Administration Medical Center in Indianapolis and the Indiana University School of Medicine, is lead author of a Viewpoint article, published in JAMA Oncology , presenting the case for interventions designed to reduce the anxiety related to cancer monitoring.
Medical research increasingly shows that observation—known as active surveillance —can be a reasonable approach to monitoring low-risk cancers in cases where treatment confers little or no benefit. While this strategy can avoid unnecessary interventions, it can also create significant anxiety for patients. "Cancer elicits fear, regardless of the disease's severity.
While observation is appropriate for certain types of cancer, like early prostate or thyroid cancer , the problem of uncertainty and stress remains after being labeled with a cancer diagnosis . There is even a name for the anxiety around the time of a follow-up medical test , called scanxiety," said Dr. Haggstrom.
No amount of information about the prognosis of a low-risk cancer can eliminate uncertainty, which can produce a variety of negative responses, including perceptions of vulnerability, feelings of fear and a propensity to avoid decision-making. Dr. Haggstrom suggests several potential interventions for consideration: In addition to testing interventions, future research should focus on understanding how uncertainty leads to anxiety .
Long-term studies are needed to track how patient responses to uncertainty change over time, especially given the extended lifespans of many patients under observation. "Health care should be patient-centered and account for any distress among patients caused by the tests they receive. While surveillance intervals may be long, once a cancer diagnosis is made, patients still live with that knowledge every day," said Dr.
Haggstrom. More information: David A. Haggstrom et al, Active Surveillance for Low-Risk Cancer—The Waiting Is the Hardest Part, JAMA Oncology (2024).
DOI: 10.1001/jamaoncol.2024.
2667.
